학술논문
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
Document Type
Academic Journal
Author
Manno D; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Patterson C; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Drammeh A; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Tetteh K; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Kroma MT; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.; Otieno GT; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Lawal BJ; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Soremekun S; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Ayieko P; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza P.O. Box 11936, Tanzania.; Gaddah A; Janssen Research and Development, 2340 Beerse, Belgium.; Kamara AB; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.; Baiden F; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Afolabi MO; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Tindanbil D; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Owusu-Kyei K; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Ishola D; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Deen GF; College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.; Keshinro B; Janssen Vaccines and Prevention, 2333 CB Leiden, The Netherlands.; Njie Y; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; EBOVAC Project Office, Kukuna Road, Kambia, Sierra Leone.; Samai M; College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.; Lowe B; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; KEMRI-Wellcome Trust Research Programme, Kilifi P.O. Box 230, Kenya.; Robinson C; Janssen Vaccines and Prevention, 2333 CB Leiden, The Netherlands.; Leigh B; College of Medicine and Allied Health Sciences, University of Sierra Leone, New England Ville, Freetown, Sierra Leone.; Drakeley C; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Greenwood B; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Watson-Jones D; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza P.O. Box 11936, Tanzania.
Source
Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2076-393X
Abstract
We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of Plasmodium falciparum antigens detected using a Luminex MAGPIX platform. Clinical malaria episodes after vaccinations were recorded as part of the trial safety monitoring. Binding antibody responses against the Ebola virus (EBOV) glycoprotein (GP) were measured 57 days post dose 1 and 21 days post dose 2 by ELISA and summarized as Geometric Mean Concentrations (GMCs). Geometric Mean Ratios (GMRs) were used to compare groups with different levels of exposure to malaria. Overall, 587 participants, comprising 188 (32%) adults (aged ≥ 18 years) and 399 (68%) children (aged 1-3, 4-11, and 12-17 years), were included in the analysis. There was no evidence that the anti-EBOV-GP antibody GMCs post dose 1 and post dose 2 differed between categories of previous malaria exposure. There was weak evidence that the GMC at 57 days post dose 1 was lower in participants who had had at least one episode of clinical malaria post dose 1 compared to participants with no diagnosed clinical malaria in the same period (GMR = 0.82, 95% CI: 0.69-0.98, p -value = 0.02). However, GMC post dose 2 was not reduced in participants who experienced clinical malaria post-dose 1 and/or post-dose 2 vaccinations. In conclusion, the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen is immunogenic in individuals with previous exposure to malaria and in those who experience clinical malaria after vaccination. This vaccine regimen is suitable for prophylaxis against Ebola virus disease in malaria-endemic regions.